Scientific Publications Search Search Author Impact Factor Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Gavvovidis, Ioannis Dr. (1) Kettenmann, Helmut Prof. Dr. (1) Kieback, Elisa Dr. (1) Lorenz, Felix Dr. (3) Obenaus, Matthias (1) Poncette, Lucia (1) Uckert, Wolfgang Prof. Dr. (10) (-) Blankenstein, Thomas Prof. Dr. (5) (-) Leisegang, Matthias Dr. (4) 1998 (2) 2000 (2) 2003 (4) 2004 (1) 2005 (3) 2006 (2) 2007 (1) 2008 (2) 2010 (4) (-) 2011 (2) 2012 (3) 2014 (2) (-) 2015 (3) 2016 (2) 2017 (2) (-) 2019 (1) Bioinformatics (1) Biology of Malignant Lymphomas (11) Genetics and Genomics of Cardiovascular Diseases (1) (-) Molecular Cell Biology and Gene Therapy (6) Molecular Immunology and Gene Therapy (14) Molecular Immunotherapy (3) Proteome Dynamics (1) Signal Transduction in Tumor Cells (1) Structural Biology of Membrane-Associated Processes (1) Systems Biology of Gene Regulatory Elements (1) 6 Results: Active Filter: Blankenstein, Thomas Prof. Dr.Leisegang, Matthias Dr.Molecular Cell Biology and Gene Therapy201120152019 Sort: Result score Newest to oldest Oldest to newest January 02, 2019 in J Clin Invest Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression L. Poncette X. Chen F.K.M. Lorenz T. Blankenstein June 01, 2015 in BIOspektrum Designer T cells - New possibilities for immunotherapy of cancer [Designer-T-Zellen - neue Möglichkeiten für die Immuntherapie von Krebs] M. Leisegang W. Uckert April 01, 2015 in Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber April 01, 2015 in Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein July 28, 2011 in Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein January 15, 2011 in Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
January 02, 2019 in J Clin Invest Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression L. Poncette X. Chen F.K.M. Lorenz T. Blankenstein
June 01, 2015 in BIOspektrum Designer T cells - New possibilities for immunotherapy of cancer [Designer-T-Zellen - neue Möglichkeiten für die Immuntherapie von Krebs] M. Leisegang W. Uckert
April 01, 2015 in Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber
April 01, 2015 in Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein
July 28, 2011 in Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
January 15, 2011 in Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
